| Dr Conrad S Balcer, DO | |
|
1241 W Stadium Blvd, Jefferson City, MO 65109-6023 | |
| (573) 635-5264 | |
| (573) 761-4611 |
| Full Name | Dr Conrad S Balcer |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Cardiovascular Disease |
| Location | 1241 W Stadium Blvd, Jefferson City, Missouri |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033199740 | NPI | - | NPPES |
| 000010688 | Other | MO | MCR GROUP |
| 260021839 | Other | MEDICARE RAILROAD | |
| 153505 | Other | HEALTHLINK | |
| 243024726 | Medicaid | MO | |
| CP9089 | Other | MO | RAILROAD GROUP |
| 112014 | Other | MO | BCBS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | R3H14 (Missouri) | Secondary |
| 207RC0000X | Internal Medicine - Cardiovascular Disease | R3H14 (Missouri) | Primary |
| Entity Name | Cole Physician Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144578659 PECOS PAC ID: 0648420810 Enrollment ID: O20121024000296 |
News Archive
Complex chemotherapy cocktails offer about one extra month of life to patients with end-stage endometrial cancer but also can result in severe, possibly fatal, side effects, according to the first systematic review of studies addressing the topic.
Martek Biosciences Corporation (Nasdaq: MATK) announced that it intends to release the results of its third quarter of fiscal 2009 on September 2, 2009, at approximately 4:00 p.m. Eastern Time (ET). Following the release, at 4:45 p.m. ET Martek will conduct a conference call to discuss these results with investors. All interested parties may listen to the call live via webcast by visiting Martek's web site at http://investors.martek.com.
Pulmatrix, Inc., previously known as Ruthigen, Inc., today announced the completion of its previously announced merger, effective June 15, 2015, and the closing of a private placement generating aggregate gross proceeds of $10.0 million. Participants in the private placement included pre-merger investors in Pulmatrix such as funds affiliated with 5AM Ventures, ARCH Venture Partners and Polaris Partners, as well as funds affiliated with Altitude Life Science Ventures.
Children who are exposed in utero to high levels of particulate air pollution during the second trimester of pregnancy may be at greater risk of developing asthma in early childhood, according to a new study presented at the 2014 American Thoracic Society International Conference.
Rice University scientists have succeeded in analyzing transmembrane protein folding in the same way they study the proteins' free-floating, globular cousins.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Conrad S Balcer, DO Po Box 104240, Jefferson City, MO 65110-4240 Ph: (573) 556-5191 | Dr Conrad S Balcer, DO 1241 W Stadium Blvd, Jefferson City, MO 65109-6023 Ph: (573) 635-5264 |
News Archive
Complex chemotherapy cocktails offer about one extra month of life to patients with end-stage endometrial cancer but also can result in severe, possibly fatal, side effects, according to the first systematic review of studies addressing the topic.
Martek Biosciences Corporation (Nasdaq: MATK) announced that it intends to release the results of its third quarter of fiscal 2009 on September 2, 2009, at approximately 4:00 p.m. Eastern Time (ET). Following the release, at 4:45 p.m. ET Martek will conduct a conference call to discuss these results with investors. All interested parties may listen to the call live via webcast by visiting Martek's web site at http://investors.martek.com.
Pulmatrix, Inc., previously known as Ruthigen, Inc., today announced the completion of its previously announced merger, effective June 15, 2015, and the closing of a private placement generating aggregate gross proceeds of $10.0 million. Participants in the private placement included pre-merger investors in Pulmatrix such as funds affiliated with 5AM Ventures, ARCH Venture Partners and Polaris Partners, as well as funds affiliated with Altitude Life Science Ventures.
Children who are exposed in utero to high levels of particulate air pollution during the second trimester of pregnancy may be at greater risk of developing asthma in early childhood, according to a new study presented at the 2014 American Thoracic Society International Conference.
Rice University scientists have succeeded in analyzing transmembrane protein folding in the same way they study the proteins' free-floating, globular cousins.
› Verified 6 days ago
Vineela Kasireddy, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1432 Southwest Blvd, Jefferson City, MO 65109 Phone: 573-632-4800 | |
Mr. Ghulam Ghous, M.D Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 1125 Madison St, Jefferson City, MO 65101 Phone: 573-632-5000 Fax: 573-634-2033 | |
Dr. Thomas W. Schneider, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1241 W Stadium Blvd, Jefferson City, MO 65109 Phone: 573-635-5264 Fax: 573-761-4351 | |
Rolando Daniel Breier, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1241 W Stadium Blvd, Jefferson City, MO 65109 Phone: 573-893-6404 Fax: 573-893-6505 | |
Chad Zeglis, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2505 Mission Dr, Jefferson City, MO 65109 Phone: 573-681-3396 Fax: 573-681-3617 | |
Dr. Rodd L Hillard, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2707 W Edgewood Dr, Jefferson City, MO 65109 Phone: 573-635-0233 Fax: 573-635-7436 |